David A. Facey

Use of a novel platelet function analyzer (PFA-100?) with high sensitivity to disturbances in von willebrand factor to screen for von willebrand's disease and other disorders

Emmanuel J. Favaloro, David A. Facey, Anthony Henniker · American Journal of Hematology · 1999 · 87 citations · Full text

Medicine, Hematology, Pathology +17

Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation

Mariagrazia De Luca, David A. Facey, Emmanuel J. Favaloro et al. · Blood · 2000 · 72 citations

Medicine, Hematology, Molecular Biology +17

Laboratory Assessment of von Willebrand Factor:<i>Use of Different Assays Can Influence the Diagnosis of von Willebrand’s Disease, Dependent on Differing Sensitivity to Sample Preparation and Differential Recognition of High Molecular Weight VWF Forms</i>

Emmanuel J. Favaloro, David A. Facey, Linda Grispo · American Journal of Clinical Pathology · 1995 · 62 citations

Medicine, Pathology, Early Detection +11

CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated.

Emmanuel J. Favaloro, Tammie Browning, David A. Facey · PubMed · 1993 · 44 citations

Life Sciences, Cell Biology, Molecular Biology +4

Identification and characterization of a novel mutation in von Willebrand factor causing type 2B von Willebrand's disease

David A. Facey, Emmanuel J. Favaloro, Jerry Koutts et al. · British Journal of Haematology · 1999 · 14 citations · Full text

Medicine, Hematology, Molecular Biology +17